DURECT (DRRX) Competitors $0.90 -0.08 (-8.13%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DRRX vs. CTMX, IPHA, PLX, MCRB, ANRO, AVTX, IFRX, DERM, CABA, and VXRTShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include CytomX Therapeutics (CTMX), Innate Pharma (IPHA), Protalix BioTherapeutics (PLX), Seres Therapeutics (MCRB), Alto Neuroscience (ANRO), Avalo Therapeutics (AVTX), InflaRx (IFRX), Journey Medical (DERM), Cabaletta Bio (CABA), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. DURECT vs. CytomX Therapeutics Innate Pharma Protalix BioTherapeutics Seres Therapeutics Alto Neuroscience Avalo Therapeutics InflaRx Journey Medical Cabaletta Bio Vaxart CytomX Therapeutics (NASDAQ:CTMX) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Do analysts prefer CTMX or DRRX? CytomX Therapeutics currently has a consensus target price of $5.77, suggesting a potential upside of 563.43%. DURECT has a consensus target price of $5.00, suggesting a potential upside of 453.34%. Given CytomX Therapeutics' higher possible upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community favor CTMX or DRRX? CytomX Therapeutics received 56 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 65.49% of users gave CytomX Therapeutics an outperform vote while only 63.84% of users gave DURECT an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% DURECTOutperform Votes31663.84% Underperform Votes17936.16% Is CTMX or DRRX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to DURECT's net margin of -198.58%. CytomX Therapeutics' return on equity of -41.47% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% DURECT -198.58%-300.62%-65.17% Does the media refer more to CTMX or DRRX? In the previous week, DURECT had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 12 mentions for DURECT and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.70 beat DURECT's score of 0.20 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DURECT 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in CTMX or DRRX? 67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, CTMX or DRRX? CytomX Therapeutics has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$101.21M0.67-$570K$0.175.12DURECT$8.59M3.26-$27.62M-$0.61-1.48 Which has more volatility & risk, CTMX or DRRX? CytomX Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. SummaryCytomX Therapeutics beats DURECT on 14 of the 17 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.42M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-1.485.5697.3414.18Price / Sales3.26348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book1.817.885.805.12Net Income-$27.62M$153.61M$119.07M$225.99M7 Day Performance-19.32%-2.00%-1.83%-1.32%1 Month Performance-36.81%-7.47%-3.64%0.60%1 Year Performance43.22%31.80%31.62%26.23% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT3.078 of 5 stars$0.90-8.1%$5.00+453.3%+39.5%$30.42M$8.55M-1.4880Analyst ForecastAnalyst RevisionNews CoverageCTMXCytomX Therapeutics4.3795 of 5 stars$0.87-2.2%$5.77+563.4%-37.4%$68.09M$101.21M5.12170Short Interest ↓IPHAInnate Pharma2.2362 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$120.64M$66.71M0.00220News CoverageGap UpPLXProtalix BioTherapeuticsN/A$1.69+3.7%N/A+22.0%$120.02M$65.49M0.00200Analyst UpgradeHigh Trading VolumeMCRBSeres Therapeutics3.8903 of 5 stars$0.81+19.0%$5.08+524.6%-16.1%$117.54M$126.32M0.00233Analyst UpgradeHigh Trading VolumeANROAlto Neuroscience3.532 of 5 stars$4.27-4.7%$20.00+368.4%N/A$115.16M$210,000.000.00N/AAnalyst RevisionAVTXAvalo Therapeutics2.3623 of 5 stars$10.90-1.4%N/A-47.4%$113.30M$820,000.000.0040Positive NewsIFRXInflaRx3.0872 of 5 stars$2.04+6.3%$8.00+292.2%+34.2%$113.06M$70,000.000.0060Gap UpDERMJourney Medical3.2915 of 5 stars$5.23-2.2%$9.38+79.3%N/A$110.89M$79.18M-5.5690Analyst RevisionPositive NewsCABACabaletta Bio2.0246 of 5 stars$2.26-11.0%$27.30+1,108.0%-87.4%$110.47MN/A-1.0550Analyst ForecastHigh Trading VolumeVXRTVaxart2.1372 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M-1.48109Analyst RevisionNews Coverage Related Companies and Tools Related Companies CTMX Competitors IPHA Competitors PLX Competitors MCRB Competitors ANRO Competitors AVTX Competitors IFRX Competitors DERM Competitors CABA Competitors VXRT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
